Centogene
178 articles about Centogene
-
There are several recent announcements of German companies opening laboratories in the U.S.
-
CENTOGENE to Open First U.S. Laboratory in Cambridge, MA Focused on Rare Genetic Diseases Diagnostics
6/5/2018
The new facility, opening on August 1, 2018, will be the central point of contact for CENTOGENE’s collaboration partners that leverage its diagnostic services in the U.S.
-
CENTOGENE to Present at the Jefferies 2018 Global Healthcare Conference
6/1/2018
CENTOGENE announced that Richard Stoffelen, Chief Financial Officer of CENTOGENE, will present at the upcoming Jefferies 2018 Global Healthcare Conference.
-
CENTOGENE to Present at the 2018 BIO International Convention
5/31/2018
CENTOGENE announced that Dr. Arndt Rolfs, CEO and Founder of CENTOGENE, will present at the BIO International Convention, June 4-7, 2018 in Boston, MA.
-
CENTOGENE and Aldeyra Therapeutics for Advancement of Novel Therapeutics for Patients with Rare Disease SLS
5/29/2018
CENTOGENE and Aldeyra today announced a collaboration with Aldeyra to identify patients with the rare disorder Sjögren-Larsson Syndrome (SLS).
-
CENTOGENE Announces Agreement with Aldeyra Therapeutics for the Advancement of Novel Therapeutics for Patients with Sjögren-Larsson Syndrome
5/29/2018
Collaboration Builds on Genetic Identification of Patients with Sjögren-Larsson Syndrome (SLS) in a Worldwide Cohort Enabling SLS Patients to Benefit from Novel Therapeutic Developments Quickly
-
CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease
5/23/2018
Centogene, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, today announced a clinical development collaboration with Orphazyme A/S.
-
CENTOGENE Highlights Solutions for Early Diagnosis of Rare Hereditary Disorders at the 2nd Annual Recent Advances in Rare Disease Conference
5/2/2018
ENTOGENE announced that its researchers will be giving a series of presentations focused on solutions for the systematic testing of risk populations.
-
Centogene Publishes Study Identifying the Best Biomarker, Lyso-Gb1, for Monitoring Response to Therapy for Patients Suffering from Gaucher Disease
4/27/2018
CENTOGENE, the worldwide leader in elucidating rare disease genetics for patients, clinicians and pharmaceutical partners, announced the publication of a scientific paper in the March issue of the American Journal of Hematology.
-
CENTOGENE Expands Executive Team, Appoints Dr. Dirk Ehlers Chief Operating Officer
4/10/2018
CENTOGENE announced the appointment of Dr. Dirk Ehlers as Chief Operating Officer (COO) and President of the Diagnostics Division.
-
CENTOGENE´s Expertise in Hypomyelinating Leukodystrophy gives New Insights in the Clinical and Genetic Spectrum of the Disease
2/28/2018
Company marks Rare Disease Day 2018 with continued commitment to reduce time to diagnosis of rare diseases.
-
CENTOGENE’s Lysosomal Storage Disorders Research to be Presented at the 14th Annual WORLDSymposium
2/1/2018
The conference, which is being held February 5-9, 2018 in San Diego, CA, presents the latest information from basic science, translational research and clinical trials for lysosomal diseases.
-
CENTOGENE's Lysosomal Storage Disorders Research to be Presented at the 14th Annual WORLDSymposium
2/1/2018
The conference, which is being held February 5-9, 2018 in San Diego, CA, presents the latest information from basic science, translational research and clinical trials for lysosomal diseases.
-
CENTOGENE Surpasses One Billion Identified Alleles within World’s Largest Patient Database of Rare Genetic Disorders
1/31/2018
CENTOGENE announced it has surpassed more than one billion identified alleles in their global patient cohorts within its database of more than 200,000 patient samples.
-
QIAGEN N.V., Centogene Ink Genetic Diseases Pact
10/10/2017
-
Centogene Raises A EUR 25 Million Series A Financing To Fuel Innovation And To Accelerate Growth Into Personalized Medicine
6/14/2017
-
FDNA And Centogene Announce First Grant Of Molecular Testing Under The Face2Gene Unknown Forum Grant Program At The American Society of Human Genetics Annual Meeting
10/17/2016
-
Centogene Revolutionizes The Clinical Interpretation Of Rare Disease Genetic Variants
4/2/2015